Talima Therapeutics, Inc. Hires New CEO
Published: Jan 16, 2008
``Martin brings to Talima the ideal combination of skills and successful experiences that will help guide the company as we pursue regulatory approval for Talima's breakthrough drug delivery technology,'' said board member and investor Fred Dotzler of De Novo Ventures.
Most recently, Martin was a senior executive at Genentech where he served in various management positions for the past eight years. While Vice President of Immunology Sales and marketing, he oversaw successful launches of both Xolair and Rituxan, and built and managed high-powered marketing and sales teams. Previously he was Senior Director of Commercial Development where he and his team of professionals, in close collaboration with R&D helped manage and prepare the Genentech product pipeline for successful launches.
Prior to Genentech, Mr. Babler worked at Eli Lilly and Company in various U.S. and international strategic positions in sales, marketing and business development. He is a graduate of the ETH in Zurich, Switzerland with a degree in Pharmaceutical Science.
``Martin was just the person we were looking for to lead the company toward commercialization of our existing product. His experience will also enable us to better exploit the potential of our technology,'' said founding CEO David Henkel-Wallace. ``When we started the company three years ago, we began outlining the characteristics of the person we would hire to take the company from proof-of-concept to commercialization. Martin meets all of those characteristics.''
Talima Therapeutics, a drug delivery company located in San Carlos California, has developed a breakthrough micro implant delivery technology for the localized application of small molecule drugs. The company's lead product is in phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the toenails. Enrollment of this phase I/II trial will continue for several months. Talima raised $19 million in Series B financing led by De Novo Ventures, US Venture Partners and Latterell Ventures in May 2007.
Contact: Talima Therapeutics Martin Babler 650 331 7246 firstname.lastname@example.org www.talima.com
Source: Talima Therapeutics